Core Points - A class action lawsuit has been filed against Bolt Biotherapeutics, Inc. for misleading statements regarding its product BDC-1001, which is designed to target HER2 in certain cancers [7][8] - The lead plaintiff deadline for the class action is September 3, 2024, and investors who purchased Bolt securities during the Class Period (February 5, 2021 to May 14, 2024) may be entitled to compensation [7][8] Summary by Category Class Action Details - Investors can join the class action without any out-of-pocket fees through a contingency fee arrangement [3] - No class has been certified yet, meaning investors are not represented by counsel unless they retain one [2] Allegations Against the Company - The lawsuit claims that Bolt overstated the effectiveness of BDC-1001 and its product pipeline, which could lead to significant operational risks [8] - The company allegedly failed to disclose that BDC-1001 was unlikely to meet its success criteria, impacting its commercial prospects [8]

Core Viewpoint - Class actions have been initiated on behalf of stockholders of SeaStar Medical Holding Corporation and Bolt Biotherapeutics, with deadlines for lead plaintiff petitions set for September 3, 2024 [1][9]. SeaStar Medical Holding Corporation - The class period for SeaStar is from October 31, 2022, to March 26, 2024, with a lead plaintiff deadline of September 3, 2024 [2]. - The merger between SeaStar and Legacy SeaStar was completed on October 28, 2022, resulting in Legacy SeaStar becoming a wholly owned subsidiary of SeaStar [4]. - Legacy SeaStar's Selective Cytopheretic Device (SCD) was highlighted for its potential in treating hyperinflammation and was intended for FDA approval under the Humanitarian Device Exemption for pediatric acute kidney injury [2][3]. - On May 9, 2023, SeaStar's HDE application for the SCD was rejected by the FDA, leading to a significant stock price drop of 39.69% [6]. - On March 27, 2024, SeaStar announced it would restate its financial statements for the fiscal year ended December 31, 2022, due to deficiencies in accounting treatment related to certain financial instruments [7]. Bolt Biotherapeutics - The class period for Bolt Biotherapeutics is from February 5, 2021, to May 14, 2024, with a lead plaintiff deadline of September 3, 2024 [13]. - The complaint alleges that Bolt's product BDC-1001 was less effective than represented, leading to overstated clinical and commercial prospects [9].

WHAT TO DO NEXT: To join the Bolt class action, go to https://rosenlegal.com/submit-form/?case_id=26946 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 3, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. DETAILS OF THE CASE: According to ...

To be considered for a lead plaintiff role, a Bolt investor must file a motion in the U.S. District Court for the Northern District of California, no later than September 3, 2024. Please contact Edelson Lechtzin LLP to discuss your investment losses, at 844-696-7492 or by e-mail at [email protected]. You can also submit your trading information online HERE. Background on Bolt Biotherapeutics, Inc. focused on developing immunotherapies for cancer treatment, primarily through its "Boltbody" pipeline. The Bolt ...

[Click here for information about joining the class action] Throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) BDC-1001 was less effective than the Company had represented to investors and was in fact unlikely to meet its pre-defined success criteria; (ii) accordingly, Defendants overstated the clinical and/or c ...

SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) securities between February 5, 2021 and May 14, 2024. Bolt, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003 ...

Core Viewpoint - Bolt Biotherapeutics has announced a significant shift in its development strategy, ceasing the development of BDC-1001 and focusing on BDC-3042 and BDC-4182 due to BDC-1001's failure to meet success criteria, leading to a substantial workforce reduction and management changes [2][10]. Company Overview - Bolt is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer treatment, primarily relying on its "Boltbody" pipeline, which includes BDC-1001, BDC-3042, and BDC-4182 [3][6]. Recent Developments - The company will reduce its workforce by approximately 50% and transition its CEO and CMO to advisory roles following the decision to halt BDC-1001's development [2]. - Analysts have downgraded Bolt's stock, citing concerns over the commercial prospects of BDC-3042 and BDC-4182, as well as the leadership changes [2]. Financial Impact - Following the announcement, Bolt's stock price dropped by $0.49 per share, or 37.12%, closing at $0.83 per share on May 15, 2024 [8]. Legal Context - A class action lawsuit has been filed against Bolt and certain officers for alleged violations of federal securities laws, claiming that the company made materially false and misleading statements regarding its business and product pipeline during the class period from February 5, 2021, to May 14, 2024 [10][11].

Click here to participate in the action. If you purchased or otherwise acquired Bolt shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. ...

NEW YORK, July 09, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ: BOLT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Bolt ...

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) between February 5, 2021 and May 14, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 3, 2024. WHAT TO DO NEXT: To join the Bolt class action, go to https://rosenlegal.com/submit-form/?case_i ...